Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Meningococcal Vaccine
Meningococcal conjugate vaccine loses effectiveness after 1 year
September 8th, 2004
The meningococcal serogroup C conjugate vaccine loses effectiveness after 1 year. According to a study from England, "The meningococcal serogroup C conjugate (MCC) vaccine program in England has successfully controlled the incidence of serogroup C disease, as a result of high short-term vaccine effectiveness and substantial herd immunity. However, the long-term effectiveness of the vaccine remains unknown. We assessed surveillance data from the 4 years since introduction of the program." "Vaccine effectiveness remained high in children vaccinated in the catch-up campaign (aged 5 months to 18 years)," reported Caroline L. Trotter and collaborators at...
Source: Vaccine Weekly (2004-09-08)
|
